SBI-5844
SBI-5844 (SBI-1275844) is a eIF4F complex inhibitor and antiviral agent. SBI-5844 disrupts the assembly of the eIF4F complex and blocks the interaction between eIF4E and eIF4G. SBI-5844 inhibits the synthesis of HCoV-OC43 nucleocapsid protein and reduces the levels of HCoV-OC43 RNA and total protein. SBI-5844 can be used in studies related to human coronavirus OC43 (HCoV-OC43) infection.
For research use only. We do not sell to patients.
- CAS No.: 832680-32-7
- Formula: C22H25NO2
- Molecular Weight:335.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
SBI-5844 (0-10 µM; 24 h) potently reduces the levels of HCoV-OC43 spike protein and nucleocapsid protein in infected Vero E6 cells[1].
SBI-5844 (0.08-10 µM; 48 h) dose-dependently and potently reduces the infection rate of HCoV-OC43 in Vero E6 cells[1].
SBI-5844 (0.625-10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels in infected Vero E6 cells in a dose-dependent manner, with nearly complete inhibition at 10 µM[1].
SBI-5844 (5-20 µM) disrupts the eIF4F complex in HCoV-OC43-infected A549 cells by reducing the binding level of eIF4G1-eIF4E and increasing the binding level of 4EBP1-eIF4E[1].
SBI-5844 (10 µM; 24 h) reduces the interaction between eIF4E and eIF4G in live A549 cells[1].
SBI-5844 (10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels and reverses infection-induced changes in host gene expression, aligning the state of both Vero E6 and A549 cells with that of uninfected cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCoV-OC43-infected Vero E6 cells
-
Concentration:10 µM
-
Incubation Time:24 h
-
Result:Reduced OC43 N-protein levels relative to DMSO-treated infected cells (normalized to HSP90).
Chemical Information
-
CAS No. 832680-32-7
-
Molecular Weight 335.44
-
Formula C22H25NO2
-
SMILES
O=C(C)C1=CN(CCCOC2=C(C)C=CC=C2)C3=C1C=CC=C3CC
-
Synonyms
SBI-1275844
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)